Assessing fitness costs in malaria parasites: a comprehensive review and implications for drug resistance management

被引:0
|
作者
Segovia, Xyonane [1 ]
Srivastava, Bhavya [2 ]
Serrato-Arroyo, Sergio [1 ]
Guerrero, Ashley [1 ]
Huijben, Silvie [1 ,3 ]
机构
[1] Arizona State Univ, Ctr Evolut & Med, Sch Life Sci, Tempe, AZ 85287 USA
[2] Univ Zurich, Zurich, Switzerland
[3] Arizona State Univ, Computat & Modeling Sci Ctr, Simon A Levin Math, Tempe, AZ 85287 USA
关键词
Malaria; Plasmodium falciparum; Fitness costs; In vitro; Rodent model; Resistance management; Pfcrt; Dhfr; Dhps; kelch13; PLASMODIUM-FALCIPARUM MALARIA; SULFADOXINE-PYRIMETHAMINE RESISTANCE; CHLOROQUINE RESISTANCE; COMPENSATORY MUTATIONS; ARTEMISININ RESISTANCE; DIHYDROFOLATE-REDUCTASE; MOLECULAR MARKERS; COTRIMOXAZOLE PROPHYLAXIS; ANTIMALARIAL RESISTANCE; ANTIBIOTIC-RESISTANCE;
D O I
10.1186/s12936-025-05286-w
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Artemisinin-based combination therapy (ACT) remains a broadly effective anti-malarial drug combination, but the emergence of resistance is threatening its effectiveness. Limiting the spread of these drug-resistant parasites and delaying the emergence of resistance in new areas are of high priority. Understanding the evolution of resistance relies on discerning the fitness costs and benefits associated with resistance mutations. If the cost associated with resistance in an untreated host is sufficiently large relative to the benefit of resistance in a treated host, then the spread of resistance can be mitigated by ensuring sufficient hosts free from that active pharmaceutical ingredient. There is no straightforward way to measure these fitness costs, and each approach that has been used has its limitations. Here, the evidence of fitness costs as measured using field data, animal models, and in vitro models is reviewed for three of the main current or past first-line treatments for malaria: chloroquine (CQ), sulfadoxine-pyrimethamine (SP), and artemisinin derivatives (ART). Despite the difficulties of assessing fitness costs, there is a good amount of evidence of fitness costs in drug-resistant Plasmodium falciparum parasites. The most persuasive evidence comes from resistance reversal observed following the cessation of the use of chloroquine. Comparable evidence cannot be obtained for SP- and ART-resistant parasites, due to the absence of complete cessation of these drugs in the field. Data from in vitro and animal models are variable. While fitness costs are often observed, their presence is not universal across all resistant strains. The extent and nature of these fitness costs can vary greatly depending on the specific genetic factors involved and the ecological context in which the parasites evolve. As a result, it is essential to avoid making broad generalizations about the prevalence or impact of fitness costs in drug-resistant malaria parasites. Focusing on fitness costs as a vulnerability in resistant parasites can guide their evolutionary trajectory towards minimizing their fitness. By accurately predicting these costs, efforts to extend the effectiveness of anti-malarials can be enhanced, limiting resistance evolution and advancing malaria control and elimination goals.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] Chloroquine Is Grossly Under Dosed in Young Children with Malaria: Implications for Drug Resistance
    Ursing, Johan
    Eksborg, Staffan
    Rombo, Lars
    Bergqvist, Yngve
    Blessborn, Daniel
    Rodrigues, Amabelia
    Kofoed, Poul-Erik
    PLOS ONE, 2014, 9 (01):
  • [42] Review of the prevalence of malaria in Zimbabwe with specific reference to parasite drug resistance (1984-96)
    Makono, R
    Sibanda, S
    TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1999, 93 (05) : 449 - 452
  • [43] The role of polyphenols in overcoming cancer drug resistance: a comprehensive review
    Dana, Maleki Parisa
    Sadoughi, Fatemeh
    Asemi, Zatollah
    Yousefi, Bahman
    CELLULAR & MOLECULAR BIOLOGY LETTERS, 2022, 27 (01)
  • [44] Concurrent management of HIV and malaria: A comprehensive review of strategies to enhance quality of life
    Obeagu, Emmanuel Ifeanyi
    Obeagu, Getrude Uzoma
    Ubosi, Nwanganga Ihuoma
    Uzoma, Ijeoma Chinwe
    Tayrab, Eltayeb Mohamed Ahmed
    MEDICINE, 2024, 103 (14)
  • [45] Risk of drug resistance in Plasmodium falciparum malaria therapy-a systematic review and meta-analysis
    Zhou, Li-Juan
    Xia, Jing
    Wei, Hai-Xia
    Liu, Xiao-Jun
    Peng, Hong-Juan
    PARASITOLOGY RESEARCH, 2017, 116 (02) : 781 - 788
  • [46] Genetic mapping of determinants in drug resistance, virulence, disease susceptibility, and interaction of host-rodent malaria parasites
    Su, Xin-zhuan
    Wu, Jian
    Xu, Fangzheng
    Pattaradilokrat, Sittiporn
    PARASITOLOGY INTERNATIONAL, 2022, 91
  • [47] Resistance of Lepidopteran Pests to Bacillus thuringiensis Toxins: Evidence of Field and Laboratory Evolved Resistance and Cross-Resistance, Mode of Resistance Inheritance, Fitness Costs, Mechanisms Involved and Management Options
    Afzal, Muhammad Babar Shahzad
    Ijaz, Mamuna
    Abbas, Naeem
    Shad, Sarfraz Ali
    Serrao, Jose Eduardo
    TOXINS, 2024, 16 (07)
  • [48] Fitness Costs of Drug Resistance Mutations in Multidrug-Resistant Mycobacterium tuberculosis: A Household-Based Case-Control Study
    Salvatore, Phillip P.
    Becerra, Mercedes C.
    zur Wiesch, Pia Abel
    Hinkley, Trevor
    Kaur, Devinder
    Sloutsky, Alexander
    Cohen, Ted
    JOURNAL OF INFECTIOUS DISEASES, 2016, 213 (01) : 149 - 155
  • [49] An online tool for mapping insecticide resistance in major Anopheles vectors of human malaria parasites and review of resistance status for the Afrotropical region
    Knox, Tessa B.
    Juma, Elijah O.
    Ochomo, Eric O.
    Jamet, Helen Pates
    Ndungo, Laban
    Chege, Patrick
    Bayoh, Nabie M.
    N'Guessan, Raphael
    Christian, Riann N.
    Hunt, Richard H.
    Coetzee, Maureen
    PARASITES & VECTORS, 2014, 7
  • [50] A multidimensional assessment of in-host fitness costs of drug resistance in the opportunistic fungal pathogen Candida glabrata
    Arastehfar, Amir
    Daneshnia, Farnaz
    Hovhannisyan, Hrant
    Cabrera, Nathaly
    Ilkit, Macit
    Desai, Jigar, V
    Gabaldon, Toni
    Shor, Erika
    Perlin, David S.
    FEMS YEAST RESEARCH, 2024, 24